Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: A
Treatment options are currently limited for persons with HIV-1 (PWH) who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. In addition, future areas of research are also identified and discussed in the main document.
Authors
- Amber F. Ladak
- David B. Cluck (ORCID: https://orcid.org/0000-0003-3656-1144)
- Caroline Derrick (ORCID: https://orcid.org/0000-0002-4404-7965)
- Milena Murray (ORCID: https://orcid.org/0000-0002-8748-185X)
- Julie B. Dumond (ORCID: https://orcid.org/0000-0002-3500-5819)
- Sarah E. Pérez
- Jeffrey Kwong (ORCID: https://orcid.org/0000-0001-9748-2234)
- Melissa D. Johnson (ORCID: https://orcid.org/0000-0002-6606-9460)
- Wesley D. Kufel (ORCID: https://orcid.org/0000-0001-7703-096X)
- Jonell B. Poe
- Daniel B. Chastain (ORCID: https://orcid.org/0000-0002-4018-0195)
- William R. Short (ORCID: https://orcid.org/0000-0003-4225-8336)
- Charlotte Bolch (ORCID: https://orcid.org/0000-0002-9797-6557)
- Nimish Patel (ORCID: https://orcid.org/0000-0003-0921-549X)
- E. Kelly Hester (ORCID: https://orcid.org/0000-0002-2985-4224)
- Elias B. Chahine (ORCID: https://orcid.org/0000-0003-1775-9497)
- Christin Kilcrease
- Spencer H. Durham (ORCID: https://orcid.org/0000-0002-6448-3879)
- Elizabeth Asiago‐Reddy (ORCID: https://orcid.org/0000-0002-0690-6474)
- Ian Thomas
- Sarah B. Jeter
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2024-11-20
- DOI
- https://doi.org/10.17615/frkv-v412
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00